世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

コンパニオン診断市場:製品・サービス毎(アッセイ、キット、ソフトウェア、サービス)、技術毎(PCR、NGS、ISH、IHC)、適応症毎(乳がん、肺がん、大腸がん、循環器系経疾患)、エンドユーザ毎(医薬品企業、CRO) - 2024年までの世界市場予測

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年9月US$4,950
シングルユーザライセンス
240 222

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)のコンパニオン診断市場に関する調査レポートです。

“The companion diagnostics market is estimated to grow at a CAGR of 15.7%”

The companion diagnostics market is projected to reach 7.3 billion by 2024 from USD 3.5 billion in 2019, at a CAGR of 15.7%. The growth of the companion diagnostics industry is tied primarily to its various advantages, the growing need for targeted therapy, the increasing importance of personalized medicine. Moreover, the increasing global incidence of cancer, ever-increasing application areas of companion diagnostics, rising demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the increasing number of clinical trials are expected to present growth opportunities for players in the market. However, the high cost of companion diagnostic tests and the uncertain reimbursement scenario in different regions affect market growth to a certain extent during the forecast period.

 “Cancer segment to witness the highest growth during the forecast period”
 
The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research. 

“Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user”

The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

“APAC market to witness the highest growth during the forecast period”

Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

A breakdown of the primary participants in this report is provided below:

- By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3-20%
- By Designation: C-level-35%, Director Level-25%, and Others-40%
- By Region: North America-45%, Europe-20%, Asia Pacific-30%, Rest of the World (RoW)-5%

The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioM-rieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), and Guardant Health, Inc. (US).

Research Coverage:

This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
- Market Development: Comprehensive information on the lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
- Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market



目次

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 MARKET SCOPE 22
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 23
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 27
2.1.2.1 Key data from primary sources 28
2.1.2.2 Key industry insights 29
2.2 MARKET SIZE ESTIMATION 30
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.4 ASSUMPTIONS FOR THE STUDY 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 39
4.1 COMPANION DIAGNOSTICS: MARKET OVERVIEW 39
4.2 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER (2018) 40
4.3 REGIONAL MIX: COMPANION DIAGNOSTICS MARKET 41
4.4 COMPANION DIAGNOSTICS MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 41
4.5 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
5.2.1 DRIVERS 44
5.2.1.1 Advantages of companion diagnostics 44
5.2.1.2 Growing need for targeted therapy 44
5.2.1.3 Growing importance of personalized medicine 45
5.2.1.4 Increasing global incidence of cancer 45
5.2.1.5 Growing application areas of companion diagnostics 46
5.2.2 RESTRAINTS 47
5.2.2.1 High cost of companion diagnostic tests 47
5.2.2.2 Uncertain reimbursement scenario in different regions 47
5.2.3 OPPORTUNITIES 48
5.2.3.1 Increasing demand for next-generation sequencing 48
5.2.3.2 Growing significance of companion diagnostics in drug development 49
5.2.3.3 Increasing number of clinical trials 50
5.2.4 CHALLENGES 51
5.2.4.1 Shortage of trained professionals 51
6 INDUSTRY INSIGHTS 52
6.1 INTRODUCTION 52
6.2 INDUSTRY TRENDS 52
6.2.1 GROWING FOCUS ON LIQUID BIOPSY IN COMPANION DIAGNOSTICS 52
6.2.2 INCREASING COLLABORATIONS 53
6.3 REGULATORY ANALYSIS 55
6.3.1 NORTH AMERICA 55
6.3.1.1 US 55
6.3.1.2 Canada 56
6.3.2 EUROPE 58
6.3.3 ASIA PACIFIC 59
6.3.3.1 Australia 59
6.3.3.2 Japan 59
6.3.3.3 China 60
6.3.3.4 India 60
6.3.4 BRAZIL 61
6.4 PRODUCT PIPELINE ANALYSIS 62
7 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 63
7.1 INTRODUCTION 64
7.2 ASSAYS, KITS, & REAGENTS 65
7.2.1 THE VOLUME OF CDX TESTS PERFORMED IN LABORATORIES IS INCREASING, WHICH SUPPORTS THE ADOPTION OF ASSAYS & KITS 65
7.3 SOFTWARE & SERVICES 66
7.3.1 THE NEED FOR EFFECTIVE DATA MANAGEMENT SOFTWARE WITHIN LABORATORIES IS INCREASING, CONTRIBUTING TO THE GROWTH OF
THE COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET 66
8 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 68
8.1 INTRODUCTION 69
8.2 POLYMERASE CHAIN REACTION (PCR) 70
8.2.1 GROWING APPLICATIONS OF PCR TECHNOLOGIES IN THE FIELD OF PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS DRIVE
THE GROWTH OF THIS SEGMENT 70
8.3 NEXT-GENERATION SEQUENCING (NGS) 72
8.3.1 THE NGS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 72
8.4 IN SITU HYBRIDIZATION (ISH) 74
8.4.1 INCREASING ADOPTION OF ISH IS MAINLY DUE TO ADVANCEMENTS IN HYBRIDIZATION AND ITS DEMAND IN SMALL-TUMOR DIAGNOSTICS 74
8.5 IMMUNOHISTOCHEMISTRY (IHC) 76
8.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES IN COMPANION DIAGNOSTICS TO DRIVE
THE GROWTH OF THIS SEGMENT 76
8.6 OTHER TECHNOLOGIES 78
9 COMPANION DIAGNOSTICS MARKET, BY INDICATION 80
9.1 INTRODUCTION 81
9.2 CANCER 82
9.2.1 BREAST CANCER 84
9.2.1.1 Breast cancer is the most common cancer among women-a key factor contributing to the large share of this market segment 84
9.2.2 LUNG CANCER 85
9.2.2.1 Growing demand for therapeutic drugs and their high efficacy in
the treatment of lung cancer increase the adoption of companion diagnostics in this segment 85
9.2.3 COLORECTAL CANCER 87
9.2.3.1 Growing need for molecular profiling of primary tumors in colorectal cancer to drive growth in this market segment 87
9.2.4 MELANOMA 89
9.2.4.1 Growing incidence of melanoma, along with the need for the early diagnosis of genetic-mutated tumors, drives the demand for companion diagnostics 89
9.2.5 GASTRIC CANCER 90
9.2.5.1 Increasing focus of market players on the development of tests and kits for gastric cancer indications to drive market growth 90
9.3 NEUROLOGICAL DISEASES 92
9.3.1 GROWING NUMBER OF DIAGNOSTIC TECHNOLOGIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES TO BOOST THE ADOPTION OF COMPANION DIAGNOSTICS IN THIS SEGMENT 92
9.4 INFECTIOUS DISEASES 93
9.4.1 GROWING FOCUS OF COMPANION DIAGNOSTIC PLAYERS ON ORPHAN INDICATIONS TO PROPEL THE GROWTH OF THIS SEGMENT DURING
THE FORECAST PERIOD 93
9.5 CARDIOVASCULAR DISEASES 95
9.5.1 GROWING DEMAND FOR TARGETED THERAPIES DUE TO HIGH INCIDENCE AND MORTALITY RATE OF CARDIOVASCULAR DISEASES TO DRIVE
GROWTH IN THIS SEGMENT 95
9.6 OTHER INDICATIONS 97
-
10 COMPANION DIAGNOSTICS MARKET, BY END USER 98
10.1 INTRODUCTION 99
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 100
10.2.1 WIDE USAGE OF COMPANION DIAGNOSTICS IN PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES OWING TO THEIR GROWING PROMINENCE IN DRUG DEVELOPMENT TO DRIVE MARKET GROWTH 100
10.3 REFERENCE LABORATORIES 101
10.3.1 GROWING INCIDENCE OF DISEASES SUCH AS CANCER AND THE RISING DEMAND FOR TARGETED THERAPIES TO DRIVE THE GROWTH OF
THIS END-USER SEGMENT 101
10.4 CONTRACT RESEARCH ORGANIZATIONS 102
10.4.1 CROS OFFER A COMPLETE RANGE OF COMPANION DIAGNOSTIC SERVICES RANGING FROM COMPANION DIAGNOSTIC DEVELOPMENT TO TARGETED THERAPY-RELATED CLINICAL TRIALS 102
10.5 OTHER END USERS 104
11 COMPANION DIAGNOSTICS MARKET, BY REGION 105
11.1 INTRODUCTION 106
11.2 NORTH AMERICA 107
11.2.1 US 111
11.2.1.1 The US is the largest market for companion diagnostics
in North America 111
11.2.2 CANADA 115
11.2.2.1 Government initiatives to promote companion diagnostics in various indications are expected to drive market growth in Canada 115
11.3 EUROPE 119
11.3.1 GERMANY 124
11.3.1.1 Germany is a major market for pharmaceutical and biotechnology products in Europe 124
11.3.2 UK 128
11.3.2.1 Growth in the country’s life science industry and increasing research are key factors driving market growth in the UK 128
11.3.3 SWITZERLAND 131
11.3.3.1 Switzerland boasts a strong research-oriented pharma industry, a key factor supporting market growth 131
11.3.4 FRANCE 135
11.3.4.1 Increasing government funding for genomics and personalized therapeutics R&D is driving market growth 135
11.3.5 ITALY 138
11.3.5.1 Growing disease prevalence has contributed to the demand for better, more powerful therapeutics in Italy 138
11.3.6 SPAIN 142
11.3.6.1 Medical institutes in Spain are increasingly focusing on cancer biomarker research 142
11.3.7 REST OF EUROPE 145
-
11.4 ASIA PACIFIC 148
11.4.1 JAPAN 153
11.4.1.1 Japan holds the largest share of the market in APAC 153
11.4.2 CHINA 156
11.4.2.1 China is one of the most prominent research markets, worldwide 156
11.4.3 INDIA 159
11.4.3.1 Initiatives by the Indian government to tackle the growing burden of cancer are expected to increase the adoption of companion diagnostics in the country 159
11.4.4 AUSTRALIA 163
11.4.4.1 Growing geriatric population in Australia has resulted in initiatives to enhance healthcare access and infrastructure 163
11.4.5 REST OF ASIA PACIFIC 166
11.5 LATIN AMERICA 169
11.5.1 BRAZIL 173
11.5.1.1 Brazil dominates the Latin American companion diagnostics market 173
11.5.2 MEXICO 176
11.5.2.1 Mexico is emerging as a prominent medical tourism hub 176
11.5.3 REST OF LATIN AMERICA 179
11.6 MIDDLE EAST & AFRICA 182
11.6.1 RISING CANCER INCIDENCE RATE HAS ATTRACTED STAKEHOLDER ATTENTION TO REGIONAL MARKETS IN MEA 182
12 COMPETITIVE LANDSCAPE 186
12.1 OVERVIEW 186
12.2 MARKET SHARE ANALYSIS 188
12.3 COMPETITIVE LEADERSHIP MAPPING, 2018 189
12.4 VENDOR INCLUSION CRITERIA 189
12.5 VENDOR DIVE 190
12.5.1 VISIONARY LEADERS 190
12.5.2 INNOVATORS 190
12.5.3 EMERGING COMPANIES 190
12.5.4 DYNAMIC DIFFERENTIATORS 190
12.6 COMPETITIVE SITUATIONS AND TRENDS 192
12.6.1 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS 193
12.6.2 ACQUISITIONS 194
-
13 COMPANY PROFILES 196
(Business overview, Products and Services offered, Recent developments, MNM view)*
13.1 F. HOFFMANN-LA ROCHE AG 196
13.2 AGILENT TECHNOLOGIES, INC. 199
13.3 QIAGEN N.V. 202
13.4 ABBOTT LABORATORIES, INC. 205
13.5 ALMAC GROUP 208
13.6 DANAHER CORPORATION 210
13.7 ILLUMINA INC. 212
13.8 BIOM-RIEUX SA 214
13.9 MYRIAD GENETICS, INC. 216
13.10 SYSMEX CORPORATION 220
13.11 THERMO FISHER SCIENTIFIC, INC. 222
13.12 ABNOVA CORPORATION 226
13.13 GUARDANT HEALTH, INC. 227
*Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 230
14.1 INSIGHTS FROM INDUSTRY EXPERTS 230
14.2 DISCUSSION GUIDE 231
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 236
14.4 AVAILABLE CUSTOMIZATIONS 238
14.5 RELATED REPORTS 238
14.6 AUTHOR DETAILS 239

 

LIST OF TABLES

TABLE 1 STANDARD CURRENCY CONVERSION RATES 23
TABLE 2 COMPANION DIAGNOSTICS MARKET SNAPSHOT, 2019 VS. 2024 34
TABLE 3 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE 48
TABLE 4 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS 49
TABLE 5 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS 50
TABLE 6 RECENT COLLABORATIONS IN THE COMPANION DIAGNOSTICS MARKET 54
TABLE 7 US: CLASSIFICATION OF MEDICAL DEVICES 55
TABLE 8 JAPAN: CLASSIFICATION OF MEDICAL DEVICES 59
TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 60
TABLE 10 INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 61
TABLE 11 COMPANION DIAGNOSTICS PRODUCT PIPELINE ANALYSIS,
BY MARKET PLAYER: CURRENT MARKET SCENARIO 62
TABLE 12 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 64
TABLE 13 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, & REAGENTS,
BY COUNTRY, 2017-2024 (USD MILLION) 66
TABLE 14 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2017-2024 (USD MILLION) 67
TABLE 15 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 69
TABLE 16 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR THE DETECTION OF RAS/BRAF MUTATION 70
TABLE 17 MAJOR PCR TESTS/KITS AVAILABLE IN THE MARKET 71
TABLE 18 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2017-2024 (USD MILLION) 72
TABLE 19 MAJOR NGS TESTS/KITS AVAILABLE IN THE MARKET 73
TABLE 20 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2017-2024 (USD MILLION) 74
TABLE 21 MAJOR ISH TESTS/KITS AVAILABLE IN THE MARKET 75
TABLE 22 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2017-2024 (USD MILLION) 76
TABLE 23 MAJOR IHC TESTS/KITS AVAILABLE IN THE MARKET 77
TABLE 24 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2017-2024 (USD MILLION) 78
TABLE 25 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2017-2024 (USD MILLION) 79
TABLE 26 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION) 81
TABLE 27 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 83
TABLE 28 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,
2017-2024 (USD MILLION) 83
TABLE 29 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY,
2017-2024 (USD MILLION) 85
TABLE 30 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY,
2017-2024 (USD MILLION) 87
TABLE 31 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2017-2024 (USD MILLION) 88
TABLE 32 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY,
2017-2024 (USD MILLION) 90
TABLE 33 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY,
2017-2024 (USD MILLION) 91
TABLE 34 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES,
BY COUNTRY, 2017-2024 (USD MILLION) 93
TABLE 35 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2017-2024 (USD MILLION) 94
TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2017-2024 (USD MILLION) 96
TABLE 37 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2017-2024 (USD MILLION) 97
TABLE 38 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION) 99
TABLE 39 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2017-2024 (USD MILLION) 100
TABLE 40 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2017-2024 (USD MILLION) 102
TABLE 41 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 103
TABLE 42 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2017-2024 (USD MILLION) 104
TABLE 43 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017-2024 (USD MILLION) 107
TABLE 44 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 108
TABLE 45 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION) 109
TABLE 46 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 109
TABLE 47 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 110
TABLE 48 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER,
BY TYPE, 2017-2024 (USD MILLION) 110
TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 111
TABLE 50 US: KEY MACROINDICATORS 112
TABLE 51 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 112
TABLE 52 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 113
TABLE 53 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 113
TABLE 54 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 114
TABLE 55 US: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 114
TABLE 56 CANADA: KEY MACROINDICATORS 116
TABLE 57 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 116
TABLE 58 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 117
TABLE 59 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 117
TABLE 60 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 118
TABLE 61 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 118
TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 121
TABLE 63 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 121
TABLE 64 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 122
TABLE 65 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 122
TABLE 66 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 123
TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 123
TABLE 68 GERMANY: KEY MACROINDICATORS 125
TABLE 69 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 125
TABLE 70 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 126
TABLE 71 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 126
TABLE 72 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 127
TABLE 73 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 127
TABLE 74 UK: KEY MACROINDICATORS 129
TABLE 75 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 129
TABLE 76 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 129
TABLE 77 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 130
TABLE 78 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 130
TABLE 79 UK: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 131
TABLE 80 SWITZERLAND: KEY MACROINDICATORS 132
TABLE 81 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION) 132
TABLE 82 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 133
TABLE 83 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 133
TABLE 84 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 134
TABLE 85 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 134
TABLE 86 FRANCE: KEY MACROINDICATORS 135
TABLE 87 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 136
TABLE 88 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 136
TABLE 89 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 137
TABLE 90 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 137
TABLE 91 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 138
TABLE 92 ITALY: KEY MACROINDICATORS 139
TABLE 93 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 139
TABLE 94 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 140
TABLE 95 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 140
TABLE 96 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 141
TABLE 97 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 141
TABLE 98 SPAIN: KEY MACROINDICATORS 143
TABLE 99 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 143
TABLE 100 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 143
TABLE 101 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 144
TABLE 102 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 144
TABLE 103 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 145
TABLE 104 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 146
TABLE 105 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 146
TABLE 106 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 147
TABLE 107 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 147
TABLE 108 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 148
TABLE 109 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 150
TABLE 110 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 150
TABLE 111 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 151
TABLE 112 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 151
TABLE 113 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 152
TABLE 114 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 152
TABLE 115 JAPAN: KEY MACROINDICATORS 153
TABLE 116 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 154
TABLE 117 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 154
TABLE 118 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 155
TABLE 119 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 155
TABLE 120 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 156
TABLE 121 CHINA: KEY MACROINDICATORS 157
TABLE 122 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 157
TABLE 123 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 157
TABLE 124 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 158
TABLE 125 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 158
TABLE 126 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 159
TABLE 127 INDIA: KEY MACROINDICATORS 160
TABLE 128 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 160
TABLE 129 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 161
TABLE 130 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 161
TABLE 131 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 162
TABLE 132 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 162
TABLE 133 AUSTRALIA: KEY MACROINDICATORS 164
TABLE 134 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 164
TABLE 135 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 164
TABLE 136 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 165
TABLE 137 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 165
TABLE 138 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 166
TABLE 139 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 167
TABLE 140 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 167
TABLE 141 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 168
TABLE 142 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 168
TABLE 143 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 169
TABLE 144 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 170
TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION) 170
TABLE 146 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 171
TABLE 147 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 171
TABLE 148 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION) 172
TABLE 149 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 172
TABLE 150 BRAZIL: KEY MACROINDICATORS 173
TABLE 151 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 174
TABLE 152 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 174
TABLE 153 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 175
TABLE 154 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 175
TABLE 155 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 176
TABLE 156 MEXICO: KEY MACROINDICATORS 177
TABLE 157 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 177
TABLE 158 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 177
TABLE 159 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 178
TABLE 160 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 178
TABLE 161 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 179
TABLE 162 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 180
TABLE 163 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 180
TABLE 164 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 181
TABLE 165 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 181
TABLE 166 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 182
TABLE 167 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017-2024 (USD MILLION) 183
TABLE 168 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 183
TABLE 169 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017-2024 (USD MILLION) 184
TABLE 170 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 184
TABLE 171 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017-2024 (USD MILLION) 185
TABLE 172 GROWTH STRATEGY MATRIX (2016-2019) 187
TABLE 173 PRODUCT LAUNCHES & APPROVALS, 2016-2019 192
TABLE 174 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS, 2016-2019 193
TABLE 175 ACQUISITIONS, 2016-2019 194
TABLE 176 EXPANSIONS, 2016-2019 195

 

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 25
FIGURE 2 PRIMARY SOURCES 27
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 29
FIGURE 4 MARKET SIZE APPROACH 31
FIGURE 5 TOP-DOWN APPROACH 31
FIGURE 6 DATA TRIANGULATION METHODOLOGY 32
FIGURE 7 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019 VS. 2024 (USD MILLION) 35
FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION) 36
FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2019 VS. 2024 (USD MILLION) 36
FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY END USER,
2019 VS. 2024 (USD MILLION) 37
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET 38
FIGURE 12 INCREASING DEMAND FOR TARGETED THERAPIES AND PERSONALIZED MEDICINE IN THE PHARMACEUTICAL INDUSTRY IS DRIVING MARKET GROWTH 39
FIGURE 13 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES COMMANDED THE LARGEST SHARE OF THE APAC COMPANION DIAGNOSTICS MARKET IN 2018 40
FIGURE 14 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD 41
FIGURE 15 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD 41
FIGURE 16 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 42
FIGURE 17 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 43
FIGURE 18 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016 45
FIGURE 19 GLOBAL CANCER INCIDENCE, 2008-2030 46
FIGURE 20 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR COMPANION
DIAGNOSTIC PRODUCTS 56
FIGURE 21 INDIA: REGULATORY PROCESS FOR IVD DEVICES 61
FIGURE 22 ASSAYS, KITS, & REAGENTS TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 64
FIGURE 23 POLYMERASE CHAIN REACTION TO DOMINATE THE COMPANION DIAGNOSTICS TECHNOLOGY MARKET DURING THE FORECAST PERIOD 69
FIGURE 24 CANCER INDICATION SEGMENT TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 81
FIGURE 25 BREAST CANCER TO DOMINATE THE COMPANION DIAGNOSTICS MARKET FOR CANCER DURING THE FORECAST PERIOD 82
FIGURE 26 GLOBAL LUNG CANCER INCIDENCE, 2012-2030 86
FIGURE 27 PHARMACEUTICAL& BIOPHARMACEUTICAL COMPANIES TO DOMINATE
THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 99
FIGURE 28 GEOGRAPHIC SNAPSHOT: CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 106
FIGURE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT 108
FIGURE 30 EUROPE: COMPANION DIAGNOSTICS MARKET SNAPSHOT 120
FIGURE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT 149
FIGURE 32 KEY DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET BETWEEN JANUARY 2016 AND MAY 2019 186
FIGURE 33 COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 188
FIGURE 34 COMPANION DIAGNOSTICS MARKET COMPETITIVE LEADERSHIP MAPPING, 2018 191
FIGURE 35 PRODUCT LAUNCHES & APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2016 & 2019 192
FIGURE 36 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT 196
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 199
FIGURE 38 QIAGEN N.V.: COMPANY SNAPSHOT 202
FIGURE 39 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT 205
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT 210
FIGURE 41 ILLUMINA INC.: COMPANY SNAPSHOT 212
FIGURE 42 BIOM-RIEUX SA: COMPANY SNAPSHOT 214
FIGURE 43 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT 216
FIGURE 44 SYSMEX CORPORATION: COMPANY SNAPSHOT 220
FIGURE 45 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 222
FIGURE 46 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT 227

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る